39 related articles for article (PubMed ID: 24985401)
1. A 48-Year-Old Man With a Hip Fracture and Skin Rash: A Case Report.
Parker JA; Hou R
AACE Clin Case Rep; 2024; 10(1):2-6. PubMed ID: 38303771
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of bone turnover markers including calculation of
Siderius M; Arends S; Kobold AM; Wagenmakers L; Koerts K; Spoorenberg A; van der Veer E
Bone Rep; 2023 Dec; 19():101724. PubMed ID: 38047270
[TBL] [Abstract][Full Text] [Related]
3. Alcohol Consumption and Risk of Fractures: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies.
Ke Y; Hu H; Zhang J; Yuan L; Li T; Feng Y; Wu Y; Fu X; Wang M; Gao Y; Huo W; Chen Y; Zhang W; Wang L; Li X; Pang J; Zheng Z; Hu F; Zhang M; Sun L; Zhao Y; Lu J; Hu D
Adv Nutr; 2023 Jul; 14(4):599-611. PubMed ID: 36966875
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel.
Velloso EDRP; Padulla GA; de Cerqueira AMM; de Sousa AM; Sandes AF; Traina F; Seguro FS; Nogueira FL; Pereira GF; Boechat JL; Pagnano KBB; Marchi LL; Ensina LF; Giavina-Bianchi M; Aun MV; Agondi RC; Santos FPS; Giavina-Bianchi P
Hematol Transfus Cell Ther; 2022; 44(4):582-594. PubMed ID: 35688791
[TBL] [Abstract][Full Text] [Related]
5. Systemic Mastocytosis: Multidisciplinary Approach.
Zanotti R; Tanasi I; Crosera L; Bonifacio M; Schena D; Orsolini G; Mastropaolo F; Tebaldi M; Olivieri E; Bonadonna P
Mediterr J Hematol Infect Dis; 2021; 13(1):e2021068. PubMed ID: 34804442
[TBL] [Abstract][Full Text] [Related]
6. Osteoporosis Caused by Systemic Mastocytosis: Prevalence in a Cohort of 8392 Patients with Osteoporosis.
Gehlen M; Schmidt N; Pfeifer M; Balasingam S; Schwarz-Eywill M; Maier A; Werner M; Siggelkow H
Calcif Tissue Int; 2021 Dec; 109(6):685-695. PubMed ID: 34223956
[TBL] [Abstract][Full Text] [Related]
7. Bone Marrow Mastocytosis: A Diagnostic Challenge.
Zanotti R; Tanasi I; Bernardelli A; Orsolini G; Bonadonna P
J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33915965
[TBL] [Abstract][Full Text] [Related]
8. Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome.
Degboé Y; Eischen M; Apoil PA; Mailhol C; Dubreuil P; Hermine O; Paul C; Bulai Livideanu C; Laroche M
Osteoporos Int; 2019 Jun; 30(6):1235-1241. PubMed ID: 30847528
[TBL] [Abstract][Full Text] [Related]
9. Multiple vertebral fractures as the first manifestation of systemic mastocytosis.
Acosta-Mérida Á; Ojeda-Bruno S
Osteoporos Int; 2019 May; 30(5):1121-1124. PubMed ID: 30770937
[TBL] [Abstract][Full Text] [Related]
10. Endocrine manifestations of systemic mastocytosis in bone.
Greene LW; Asadipooya K; Corradi PF; Akin C
Rev Endocr Metab Disord; 2016 Sep; 17(3):419-431. PubMed ID: 27239674
[TBL] [Abstract][Full Text] [Related]
11. Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.
Rossini M; Zanotti R; Orsolini G; Tripi G; Viapiana O; Idolazzi L; Zamò A; Bonadonna P; Kunnathully V; Adami S; Gatti D
Osteoporos Int; 2016 Aug; 27(8):2411-21. PubMed ID: 26892042
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis.
Rossini M; Zanotti R; Bonadonna P; Artuso A; Caruso B; Schena D; Vecchiato D; Bonifacio M; Viapiana O; Gatti D; Senna G; Riccio A; Passalacqua G; Pizzolo G; Adami S
Bone; 2011 Oct; 49(4):880-5. PubMed ID: 21782049
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis.
van der Veer E; van der Goot W; de Monchy JG; Kluin-Nelemans HC; van Doormaal JJ
Allergy; 2012 Mar; 67(3):431-8. PubMed ID: 22229787
[TBL] [Abstract][Full Text] [Related]
14. Bone involvement and osteoporosis in mastocytosis.
Rossini M; Zanotti R; Viapiana O; Tripi G; Orsolini G; Idolazzi L; Bonadonna P; Schena D; Escribano L; Adami S; Gatti D
Immunol Allergy Clin North Am; 2014 May; 34(2):383-96. PubMed ID: 24745681
[TBL] [Abstract][Full Text] [Related]
15. Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.
Siris ES; Baim S; Nattiv A
Postgrad Med; 2010 Jan; 122(1):82-90. PubMed ID: 20107292
[TBL] [Abstract][Full Text] [Related]
16. Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis.
van der Veer E; Arends S; van der Hoek S; Versluijs JB; de Monchy JGR; Oude Elberink JNG; van Doormaal JJ
J Allergy Clin Immunol; 2014 Dec; 134(6):1413-1421. PubMed ID: 24985401
[TBL] [Abstract][Full Text] [Related]
17. Fracture Risk Reduction by Bisphosphonates in Mastocytosis?
Onnes MC; van Doormaal JJ; van der Veer E; Versluijs JB; Arends S; Oude Elberink HNG
J Allergy Clin Immunol Pract; 2020; 8(10):3557-3564. PubMed ID: 32673882
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
